Story perspectives

Breakthrough Study Reveals 29% Survival Rate in MBC Treatment

1/17/2025

31 7

Summary

Story summary

Cleveland Clinic's groundbreaking research uncovers the traits of exceptional responders to metastatic breast cancer (MBC) treatment, boasting a promising 29% five-year survival rate. At the San Antonio Breast Cancer Symposium, 27 patients showcased remarkable treatment responses. Furthermore, the MECCA trial highlights that combining metronomic capecitabine with an aromatase inhibitor significantly boosts survival for hormone receptor-positive, HER2-negative MBC patients.

1 of 1

Story summary

Cleveland Clinic's groundbreaking research uncovers the traits of exceptional responders to metastatic breast cancer (MBC) treatment, boasting a promising 29% five-year survival rate. At the San Antonio Breast Cancer Symposium, 27 patients showcased remarkable treatment responses. Furthermore, the MECCA trial highlights that combining metronomic capecitabine with an aromatase inhibitor significantly boosts survival for hormone receptor-positive, HER2-negative MBC patients.